Recent Advances in Understanding the Molecular Pathophysiology of Angiotensin II Receptors: Lessons From

Satoru Eguchi1, Matthew A Sparks2, Hisashi Sawada3

  • 1Sol Sherry Thrombosis Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA.

Insights

The renin-angiotensin system (RAS) impacts blood pressure and organ damage. This review explores cell-specific roles of angiotensin II receptors in cardiovascular and kidney health and disease.

Area of Science:

  • Physiology
  • Endocrinology
  • Cardiovascular Science

Background:

  • The renin-angiotensin system (RAS) regulates blood pressure, sodium balance, and vascular tone.
  • Angiotensin II (Ang II) and its type 1 receptor (AT1R) are implicated in hypertension and end-organ damage.
  • Emerging evidence suggests complex, context-dependent roles for RAS components, including beneficial effects mediated by other peptides and receptors.

Purpose of the Study:

  • To review the cell type-specific functions of Ang II receptors in cardiovascular and kidney tissues.
  • To elucidate the significance of these receptors in both physiological and pathological conditions.
  • To highlight recent findings from cell type-selective gene deletion studies.

Main Methods:

  • Review of current literature on the renin-angiotensin system.
  • Analysis of data from cell type-selective gene-deleted mouse models.
  • Focus on Ang II receptor expression and function in vascular, cardiac, and kidney epithelial cells.

Main Results:

  • Ang II type 1 receptor plays a critical role in cardiovascular and kidney diseases, independent of blood pressure.
  • The RAS exhibits both detrimental and beneficial effects on the cardiovascular system, depending on activated components.
  • Angiotensin 1-7 and Ang II type 2 receptors may act as counter-regulatory pathways.

Conclusions:

  • Understanding cell-specific roles of Ang II receptors is crucial for deciphering RAS functions in health and disease.
  • Further research is needed to resolve controversies regarding tissue-level blood pressure regulation by the RAS.
  • Targeting specific RAS components offers potential for novel therapeutic strategies in cardiovascular and kidney diseases.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
786
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
699
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
698
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.5K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
490